Stryker delivered 9% organic sales growth in the second quarter of 2026, with adjusted EPS rising 17.9% to $3.69, despite ongoing impacts from a cybersecurity incident and a Peripheral Vascular supply disruption. MedSurg & Neurotechnology grew 9.2% and Orthopaedics grew 8.6%, while international sales rose 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako robotics surpassed 2.5 million procedures globally across 47 countries, with U.S. knee sales up 6.2% and Ortho Tech up 9.2% on robust installations. Management maintained full-year EPS guidance of $14.95-$15.10, though the Peripheral Vascular disruption is expected to drag organic growth by roughly 50-75 basis points until backorders normalize by the end of the third quarter. The Zacks Consensus Estimate for 2026 earnings has risen 3 cents to $15.02 per share over the past 60 days.
Stryker CorporationStrong organic sales growth and Mako robotics surpassing 2.5 million procedures indicate robust demand.
Globus Medical
The Cooper Companies, Inc
West Pharmaceutical Services Inc